Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.

Frontiers in endocrinology - 1 Jan 2024

Zhang Yi, Ou Guangyang, Peng Lei, Pan Jian, Zhang Shaohua, Shi Jianguo

Abstract excerpt

Objective: The impact of lipid-lowering medications on chronic kidney disease (CKD) remains a subject of debate. This Mendelian randomization (MR) study aims to elucidate the potential effects of lipid-lowering drug targets on CKD development. Methods: We extracted 11 genetic variants encoding targets of lipid-lowering drugs from published genome-wide association study (GWAS) summary statistics, encompassing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PPARA gene
Share to Angiopoietin-Like Protein 3
Share to CD14 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Hypolipidemic Agents

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Renal Insufficiency, Chronic

Source

Open in PubMed Open full text

Identifiers

PMID: 39877840
DOI: 10.3389/fendo.2024.1434145
PMCID: PMC11772207

Genes

ANGPTL3
LDLR
ABCG5
ABCG8
APOB
APOC3
CD14
HMGCR
LPL
NPC1L1
PCSK9
PPARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.PMID 39877840Read ↗

Lipid-lowering drugs and risk of rapid renal function decline: a mendelian randomization study.Semantic proximity Read ↗

Lipid-Lowering Drugs and Risk of Rapid Renal Function Decline: A Mendelian Randomization StudySemantic proximity Read ↗

Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney DiseasesSemantic proximity Read ↗

An interracial Mendelian analysis revealed a link between lipid-lowering drugs and renal failure.Semantic proximity Read ↗

Immune cell signatures and inflammatory mediators: unraveling their genetic impact on chronic kidney disease through Mendelian randomization.Semantic proximity Read ↗

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization studySemantic proximity Read ↗

Genetic association of lipids and lipid-lowering drug targets with the risk of type 1 diabetes and its complicationsSemantic proximity Read ↗

Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study.Semantic proximity Read ↗

Causal Effect Between Total Cholesterol and HDL Cholesterol as Risk Factors for Chronic Kidney Disease: A Mendelian Randomization StudySemantic proximity Read ↗

Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studySemantic proximity Read ↗

Causal Effect Between Total Cholesterol and Hdl Cholesterol as Risk Factors for Chronic Kidney Disease: A Mendelian Randomization StudySemantic proximity Read ↗

HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.